{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:48:41Z","timestamp":1768549721952,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1007\/bf02685901","type":"journal-article","created":{"date-parts":[[2007,8,11]],"date-time":"2007-08-11T02:13:45Z","timestamp":1186798425000},"page":"39-43","source":"Crossref","is-referenced-by-count":23,"title":["The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Hakan","family":"Karagol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinar","family":"Saip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazim","family":"Uygun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Caloglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yesim","family":"Eralp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faruk","family":"Tas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Aydiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkan","family":"Topuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02685901_CR1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/9780470987360.ch35","volume-title":"Evidence-Based Oncology","author":"PA Vasey","year":"2003","unstructured":"Vasey PA. Ovarian and fallopian tube cancers. In: Williams C (ed). Evidence-Based Oncology, 1st ed. BMJ Books: London, 2003, pp 377\u2013393.","edition":"1st ed."},{"key":"BF02685901_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","volume":"5","author":"M Markman","year":"2000","unstructured":"Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26\u201335.","journal-title":"Oncologist"},{"key":"BF02685901_CR3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0140-6736(96)06071-0","volume":"349","author":"GB Kristensen","year":"1997","unstructured":"Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997;349:113\u2013117.","journal-title":"Lancet"},{"key":"BF02685901_CR4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","volume":"68","author":"KD Hatch","year":"1991","unstructured":"Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second line therapy in 105 patients. Cancer 1991;68:269\u2013271.","journal-title":"Cancer"},{"key":"BF02685901_CR5","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.1993.11.10.1957","volume":"11","author":"JD Ahlgren","year":"1993","unstructured":"Ahlgren JD, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993;11:1957\u20131968.","journal-title":"J Clin Oncol"},{"key":"BF02685901_CR6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1525-1438.1995.05040301.x","volume":"5","author":"J Velden Van Der","year":"1995","unstructured":"Van Der Velden J, Gitsch G, Wain GV, Friedlander ML, Hacker NF. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Oncol 1995;5:301\u2013305.","journal-title":"Int J Gynecol Oncol"},{"key":"BF02685901_CR7","first-page":"2639","volume":"15","author":"W Jager","year":"1995","unstructured":"Jager W, et al. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res 1995;15:2639\u20132642.","journal-title":"Anticancer Res"},{"key":"BF02685901_CR8","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0959-8049(00)00228-8","volume":"36","author":"C Trope","year":"2000","unstructured":"Trope C, Marth C, Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 2000;36:S59\u201367.","journal-title":"Eur J Cancer"},{"key":"BF02685901_CR9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1210\/en.2003-0709","volume":"145","author":"S Mabuchi","year":"2004","unstructured":"Mabuchi S, et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or sensitivity to cisplatin. Endocrinology 2004;145:1302\u20131313.","journal-title":"Endocrinology"},{"key":"BF02685901_CR10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ygyno.2004.11.023","volume":"96","author":"R Zhoua","year":"2005","unstructured":"Zhoua R, Treeck O, Horn F, Ortmann O. Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells. Gynecol Oncol 2005;96:678\u2013683.","journal-title":"Gynecol Oncol"},{"key":"BF02685901_CR11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/bjc.1994.326","volume":"70","author":"EF Mcclay","year":"1994","unstructured":"Mcclay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 1994;70:449\u2013452.","journal-title":"Br J Cancer"},{"key":"BF02685901_CR12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/gyno.2001.6489","volume":"84","author":"JL Peraz-Gracia","year":"2001","unstructured":"Peraz-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systemic review of the literature and implications for future research. Gynecol Oncol 2001;84:201\u2013209.","journal-title":"Gynecol Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02685901.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02685901\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02685901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T08:11:18Z","timestamp":1558339878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02685901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["BF02685901"],"URL":"https:\/\/doi.org\/10.1007\/bf02685901","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}